BioSpace News Archive

Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023, being held August 29 – September 1, 2023 in Jerusalem, Israel.

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has submitted an Orphan Drug Designation application for XORLO™ to the European Medicines Agency (the “EMA”).

Longeveron Inc. announced that the Company’s management will be participating in the 149th Annual Conference of the National Investment Banking Association, to be held in Fort Lauderdale, FL, September 6-7, 2023.

Mycobacterium tuberculosis (Mtb) is the pathogen that causes tuberculosis (TB), the world’s deadliest infectious disease.

Mainstay Medical Holdings plc today announced the completion of enrollment in its RESTORE randomized clinical study of ReActiv8 for the treatment of intractable chronic low back pain.

Certara (Nasdaq: CERT), a global leader in biosimulation, today announced that the Simcyp group has been awarded two new grants from the U.S. Food and Drug Administration (FDA) to expand its predictive models for assessing drug virtual bioequivalence (VBE) and to create a formulation toolbox for topically applied drugs.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that company executives will participate in three upcoming healthcare investment conferences.

Amsterdam, Netherlands and Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Resverlogix Corp. (TSX: RVX) (“Resverlogix”) (TSX:RVX) today announced that new guidelines published by the European Society of Cardiology

Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia” or the “Company”) is pleased to provide its unaudited financial results for the three months ended June 30, 2023. These filings and additional information regarding Britannia are available for review on SEDAR at www.sedar.com.

Immune Therapeutics, Inc. d/b/a Biostax Corp., a hub-and-spoke biotech development engine, announces the signing of a research collaboration agreement with Immgenuity, Inc.